趨化因子C-X-C-基元受體4(CXCR4)重組蛋白
Recombinant Chemokine C-X-C-Motif Receptor 4 (CXCR4)
CD184; Fusin; NPYR; HSY3RR; LAP3; LCR1; LESTR; NPY3R; NPYRL; WHIM; Leukocyte-derived seven transmembrane domain receptor; Lipopolysaccharide-associated protein 3
- 編號RPA940Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位細(xì)胞膜, 溶酶體
- 預(yù)測分子量13.6kDa
- 實際分子量16kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Asp262~Ser352 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)8.6
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1046 ¥ 2616 ¥ 5232 ¥ 15696 ¥ 39240
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure . Gene Sequencing (extract)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA940Hu01 | 趨化因子C-X-C-基元受體4(CXCR4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPA940Hu21 | 趨化因子C-X-C-基元受體4(CXCR4)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| PAA940Hu08 | 趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA940Hu01 | 趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體 | WB; IHC; ICC; IP. |
| FAA940Hu01 | 抗趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體 | Flow cytometry. |
| FAA940Hu41 | 抗趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體(藻紅素標(biāo)記) | Flow cytometry. |
| FAA940Hu51 | 抗趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體(別藻藍(lán)蛋白標(biāo)記) | Flow cytometry. |
| FAA940Hu81 | 抗趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體(異硫氰酸熒光素標(biāo)記) | Flow cytometry. |
| MAA940Hu21 | 趨化因子C-X-C-基元受體4(CXCR4)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA940Hu22 | 趨化因子C-X-C-基元受體4(CXCR4)單克隆抗體 | WB; IHC; ICC; IP. |
| RAA940Hu21 | 趨化因子C-X-C-基元受體4(CXCR4)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| SEA940Hu | 趨化因子C-X-C-基元受體4(CXCR4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA940Hu | 趨化因子C-X-C-基元受體4(CXCR4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| International Journal of Cancer | Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model [Wiley: source] |
| Plos one | Emodin Suppresses Migration and Invasion through the Modulation of CXCR4 Expression in an Orthotopic Model of Human Hepatocellular Carcinoma [PubMed: PMC3589458] |
| Atherosclerosis | The non-alcoholic fraction of beer increases stromal cell derived factor 1 and the number of circulating endothelial progenitor cells in high cardiovascular risk subjects: A randomized clinical trial [Pubmed:24530788] |
| Pharmacol Rep.? | Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression [Pubmed:25150002] |
| Pharmacological Reports | Serum concentrations of chemokines (CCL-5 and CXCL-12), chemokine receptors (CCR-5 and CXCR-4), and IL-6 in patients with posttraumatic stress disorder and avoidant personality disorder [PubMed: 26481549] |
| Pharmacological Reports | A study of chemokines, chemokine receptors and interleukin-6 in patients with panic disorder, personality disorders and their co-morbidity [Pubmed:27208878] |
| BMC Cancer.? | Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists [pmc:PMC4866076] |
| Frontiers in Bioengineering and Biotechnology | Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison?… [Pubmed:29670878] |
留言咨詢
